Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2015-03-31
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression
NCT00703742
Function of Catecholamines in the Brain During Depression
NCT00082030
Beta-CIT-SPECT and Neurophysiology in Depression
NCT00145132
Escitalopram and Depression in Elderly Alzheimer's Patients
NCT00488670
Aging Brain Changes, Executive Dysfunction and Depression
NCT00918684
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MDD
Currently unmedicated patients with a depressive episode in the context of unipolar major depression
No interventions assigned to this group
Control
Healthy Controls
No interventions assigned to this group
Alzheimer's Disease
Patients with Alzheimer's disease
No interventions assigned to this group
Alcoholism
Subjects with alcoholism
No interventions assigned to this group
Schizophrenia
Subjects with before and schizophrenia prior to and during medication with clozapine, olanzapine or aripiprazole
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* at least 18 points or more on the BDI and HAMD-17
* diagnosed AD
* subjects with schizophrenia
* intended therapy with clozapine, olanzapine or aripiprazole
* BMI: 18 - 29,9 kg/m2
* subjects with alcoholism who either still consume alcohol or are abstinent for at least 4 weeks
Exclusion Criteria
* current history of any neurological or other serious medical condition
* any psychopharmacological treatment or substance use within the last two weeks or 5 half-lives (whichever is longer) of the respective substance
* any oral or topical application of retinoid-containing preparations within the last 3 months
AD-Group
* any other neurodegenerative disorder
* any oral or topical application of retinoid-containing preparations within the last 3 months
Schizophrenia-Group
* presence of diabetes or pathological glucose tolerance
* presence of and chronic inflammatory disease
* any psychopharmacological treatment of clozapine, olanzapine or aripiprazole within the last 3 months
* any oral or topical application of retinoid-containing preparations within the last 3 months
Alcoholism-Group
* any oral or topical application of retinoid-containing preparations within the last 3 months
* current history of any neurological or other serious medical condition despite liver diseases
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Charite University, Berlin, Germany
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Julian Hellmann-Regen
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Isabella Heuser, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Chair: Department of Psychiatry, Charité, CBF
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Psychiatry, Charité - Campus Benjamin Franklin
Berlin, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EA4/002/13
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.